Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial.

Publikation

Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial.

Wissenschaftlicher Artikel/Review - 12.04.2022

Scheller Bruno, Rissanen Tuomas T, Farah Ahmed, Ohlow Marc-Alexander, Mangner Norman, Wöhrle Jochen, Möbius-Winkler Sven, Weilenmann Daniel, Leibundgut Gregor, Cuculi Florim, Gilgen Nicole, Coslovsky Michael, Mahfoud Felix, Jeger Raban V, BASKET-SMALL 2 Investigators

Zitation

Scheller B, Rissanen T, Farah A, Ohlow M, Mangner N, Wöhrle J, Möbius-Winkler S, Weilenmann D, Leibundgut G, Cuculi F, Gilgen N, Coslovsky M, Mahfoud F, Jeger R, BASKET-SMALL 2 Investigators. Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. Circ Cardiovasc Interv 2022; 15:e011569.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Circ Cardiovasc Interv 2022; 15

Veröffentlichungsdatum

12.04.2022

eISSN (Online)

1941-7632

Seiten

e011569

Kurzbeschreibung/Zielsetzung

Patients at high-bleeding risk (HBR) undergoing percutaneous coronary intervention represent a challenging patient population. The use of drug-coated balloon (DCB) allows shorter duration of dual antiplatelet therapy compared with drug-eluting stents (DES) and reduces thrombotic risk due to the absence of a permanent implant. The present analysis aimed to investigate if the effect of DCB versus DES differed between patients with and without HBR treated with percutaneous coronary intervention in small coronary arteries.